Clearside Biomedical Stock Price, News & Analysis (NASDAQ:CLSD) $1.10 +0.07 (+6.80%) (As of 02:33 PM ET) Add Compare Share Share Today's Range$1.06▼$1.1350-Day Range$0.68▼$1.1452-Week Range$0.65▼$1.85Volume149,375 shsAverage Volume154,325 shsMarket Capitalization$68.65 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Clearside Biomedical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside358.7% Upside$5.00 Price TargetShort InterestHealthy0.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingAcquiring Shares$65,245 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.56) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector554th out of 951 stocksPharmaceutical Preparations Industry264th out of 439 stocks 3.5 Analyst's Opinion Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Clearside Biomedical has a forecasted upside of 358.7% from its current price of $1.09.Amount of Analyst CoverageClearside Biomedical has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.57% of the float of Clearside Biomedical has been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently increased by 0.79%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLSD. Previous Next 3.3 News and Social Media Coverage News SentimentClearside Biomedical has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Clearside Biomedical this week, compared to 1 article on an average week.Search Interest8 people have searched for CLSD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,245.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.80% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 13.70% of the stock of Clearside Biomedical is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.56) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearside Biomedical has a P/B Ratio of 6.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Clearside Biomedical Stock (NASDAQ:CLSD)Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Read More CLSD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLSD Stock News HeadlinesDecember 1, 2023 | americanbankingnews.comClearside Biomedical (NASDAQ:CLSD) Coverage Initiated by Analysts at StockNews.comNovember 23, 2023 | finanznachrichten.deClearside Biomedical, Inc.: Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateDecember 4, 2023 | Edge On The Street (Ad)Is This The Most Overlooked Gold Investment Strategy of 2024?There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.November 15, 2023 | markets.businessinsider.comClearside Biomedical Earns Buy Rating Amid Successful Clinical Trials and Promising Partnerships: An Analysis by Jonathan WollebenNovember 14, 2023 | markets.businessinsider.comPromising Developments and Financial Stability Bolster Buy Rating for Clearside BiomedicalNovember 14, 2023 | finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | benzinga.comClearside Biomedical: Q3 Earnings InsightsNovember 13, 2023 | finance.yahoo.comClearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateDecember 4, 2023 | Edge On The Street (Ad)Is This The Most Overlooked Gold Investment Strategy of 2024?There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.November 13, 2023 | finance.yahoo.comClearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 12, 2023 | msn.comClearside Biomedical Q3 2023 Earnings PreviewNovember 8, 2023 | finance.yahoo.comClearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare ConferenceNovember 7, 2023 | finance.yahoo.comClearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual MeetingNovember 6, 2023 | markets.businessinsider.comClearside Biomedical Receives Buy Rating Based on Promising Developments and Potential Market OpportunitiesNovember 6, 2023 | morningstar.comClearside Biomedical Inc CLSDNovember 3, 2023 | benzinga.comBioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®November 3, 2023 | finance.yahoo.comBioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®November 2, 2023 | finance.yahoo.comClearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual MeetingNovember 1, 2023 | finance.yahoo.comClearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMDOctober 31, 2023 | finance.yahoo.comClearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023October 16, 2023 | finance.yahoo.comClearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific MeetingOctober 4, 2023 | finance.yahoo.comClearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in ChinaSeptember 19, 2023 | finance.yahoo.comClearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare ConferenceSeptember 14, 2023 | benzinga.comChief Financial Officer at Clearside Biomedical Exercises Options Worth $29KAugust 19, 2023 | finanznachrichten.deClearside Biomedical, Inc.: Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 15, 2023 | markets.businessinsider.comJMP Securities Sticks to Its Buy Rating for Clearside Biomedical (CLSD)August 14, 2023 | finance.yahoo.comClearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLSD CUSIPN/A CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees36Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+358.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,950,000.00 Net Margins-1,687.74% Pretax Margin-1,687.74% Return on Equity-533.87% Return on Assets-88.01% Debt Debt-to-Equity RatioN/A Current Ratio5.28 Quick Ratio5.28 Sales & Book Value Annual Sales$1.33 million Price / Sales51.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book6.06Miscellaneous Outstanding Shares62,410,000Free Float56,293,000Market Cap$68.03 million OptionableOptionable Beta2.30 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. George M. Lasezkay J.D. (Age 71)Pharm.D., Pharma.D., President, CEO & Director Comp: $816.4kMr. Charles A. Deignan (Age 59)Chief Financial Officer Comp: $536.95kDr. Thomas A. Ciulla M.B.A. (Age 59)M.D., Chief Medical Advisor-Retina Comp: $597.21kMs. Jenny R. Kobin (Age 56)Head of Investor Relations Mr. Rick McElhenyVice President of Corporate DevelopmentMr. Rafael V. Andino (Age 58)Senior Vice President of Engineering & Manufacturing Ms. Susan L. Coultas Ph.D.Chief Clinical OfficerMr. Leslie B. Zacks (Age 54)Secretary More ExecutivesKey CompetitorsTiziana Life SciencesNASDAQ:TLSAEyenoviaNASDAQ:EYENAdageneNASDAQ:ADAGKezar Life SciencesNASDAQ:KZRAclaris TherapeuticsNASDAQ:ACRSView All CompetitorsInsiders & InstitutionsCarmignac GestionSold 267,600 shares on 11/29/2023Ownership: 3.417%Bradford T WhitmoreBought 64,366 shares on 11/1/2023Total: $47,630.84 ($0.74/share)Simplex Trading LLCBought 600 shares on 11/1/2023Ownership: 0.000%Bradford T WhitmoreBought 600 shares on 10/30/2023Total: $414.00 ($0.69/share)Nancy J HutsonBought 10,000 shares on 10/3/2023Total: $8,600.00 ($0.86/share)View All Insider TransactionsView All Institutional Transactions CLSD Stock Analysis - Frequently Asked Questions Should I buy or sell Clearside Biomedical stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSD shares. View CLSD analyst ratings or view top-rated stocks. What is Clearside Biomedical's stock price target for 2024? 4 brokerages have issued 1-year price objectives for Clearside Biomedical's stock. Their CLSD share price targets range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 358.7% from the stock's current price. View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts. How have CLSD shares performed in 2023? Clearside Biomedical's stock was trading at $1.12 on January 1st, 2023. Since then, CLSD stock has decreased by 2.7% and is now trading at $1.09. View the best growth stocks for 2023 here. When is Clearside Biomedical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our CLSD earnings forecast. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.22 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 533.87% and a negative net margin of 1,687.74%. During the same quarter in the prior year, the business earned ($0.13) EPS. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), Organigram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE). When did Clearside Biomedical IPO? (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. Who are Clearside Biomedical's major shareholders? Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Carmignac Gestion (3.42%), Simplex Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Richard T Burke and Thomas Ciulla. View institutional ownership trends. How do I buy shares of Clearside Biomedical? Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CLSD) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.